MyChesCo on MSN8h
FDA Approves GSK’s Blujepa as First New Oral Antibiotic for UTIs in 30 Years
The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...
Millions of women get painful UTIs that keep coming back. A new kind of antibiotic may help break the cycle
The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...
McKnight's Long-Term Care News3d
FDA approves gepotidacin antibiotic for uncomplicated urinary tract infections
The Food and Drug Administration has approved a new antibiotic that can treat uncomplicated urinary tract infections, or ...
Everyday Health on MSN3d
FDA Approves the First New UTI Antibiotic in Nearly 30 Years
This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...
US approves new antibiotic for urinary tract infections
US health regulators have approved a new antibiotic to treat urinary tract infections, a problem affecting more than 100 ...
Zacks Investment Research on MSN5d
GSK Secures FDA Nod for Oral Antibiotic to Treat Urinary Tract Infection
GSK plc GSK announced that the FDA has approved its oral antibiotic gepotidacin for treating uncomplicated urinary tract ...
The American Journal of Managed Care6d
FDA Approves First New Class of Oral Antibiotics for Uncomplicated UTIs in Nearly 30 Years
The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...
MedCity News5d
FDA Approves First-in-Class GSK Antibiotic for Common Type of Urinary Tract Infection
A GSK pill that offers a lower potential for drug resistance is now FDA approved as a new treatment for a common type of urinary tract infection, the first new oral antibiotic for this indication ...
WLWT6d
FDA approves a new kind of oral antibiotic to treat urinary tract infections
""We are proud to have developed Blujepa, the first in a new class of oral antibiotics for in nearly three decades, and to bring another option to patients given recurrent infections and rising ...